360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Grifols SA

Type: Company

Name: Grifols SA (Grifols S.A)

Nationality: Spain

Web Address: http://www.grifols.com/

Fact Sheet: Fact Sheet for Grifols SA

First reported 6 hours ago - Updated 5 hours ago - 1 reports

Global Plasma Market 2013 - Report

Research and Markets (http://www.researchandmarkets.com/research/glq7x2/global_plasma) has announced the addition of the "Global Plasma Market 2012-2016" report to their offering. Global Plasma Market To Grow At A CAGR Of 10.31 Percent Over The Period ... [Published Individual.com - 6 hours ago]

Entities: Market, CSL Behring, Grifols SA

First reported Jun 07 2013 - Updated Jun 07 2013 - 1 reports

University of Florida College of Medicine

Grifols announces encouraging results from AAT deficiency study

Grifols SA, a healthcare company, has announced results from a study demonstrating that a higher dose of PROLASTIN-C increased levels of the alpha1 protein in patients with alpha1antitrypsin, or AAT, deficiency to levels that are considered within the ... [Published Individual.com - Jun 07 2013]

Entities: Grifols SA, Serum, Infusion, University of Florida College of Medicine, Protein

First reported Jun 03 2013 - Updated Jun 04 2013 - 2 reports

Alzheimer's Leaves Clues in Blood

With approximately 75% of the estimated 36 million Alzheimer's sufferers worldwide yet to receive a reliable diagnosis, the potential impact on the lives of possible sufferers, present and future, could be huge. Alzheimer's disease is a neurodegenerative ... [Published Newswit.com - Jun 04 2013]

Entities: Alzheimer's Disease, Peptide, Grifols SA, Blood Cell, etiology

First reported Jun 03 2013 - Updated Jun 03 2013 - 1 reports

Grifols SA

Cadence Pharmaceuticals Announces Strategic Plan to Secure Long-Term Manufacture and Supply of OFIRMEV® (acetaminophen) Injection

/PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced a new supply ... [Published Longitude Capital - Jun 03 2013]

Entities: Grifols SA, Cadence Pharmaceuticals Inc, Paracetamol

First reported Jun 03 2013 - Updated Jun 03 2013 - 1 reports

Morgan Stanley & Co

European broker round-up: Morgan Stanley reviews Spanish utilities

Top European stock recommendations of the day: Repsol: Citi maintains BUY rating with a price target of 20. Ferrovial: Citi issues BUY rating and raises price target to 14.30 from 12.70. EADS: UBS confirms BUY rating with a price target of 49. Ebro Foods: ... [Published BIBM Banca Mora - Jun 03 2013]

Entities: Morgan Stanley & Co, UBS AG, EBRO Foods SA

First reported May 30 2013 - Updated May 30 2013 - 1 reports

Grifols opens new immunoglobulin purification plant in US

Grifols, a pharmaceutical company, has opened the company's new plant for the purification of intravenous immunoglobulin, or IVIG, a plasma protein, which the company markets under the Flebogamma and Gamunex brands. The new plant forms part of Grifols' ... [Published Individual.com - May 30 2013]

Entities: Grifols SA, Immunoglobulin, Plasma Proteins, Los Angeles, Biotechnology

First reported May 29 2013 - Updated May 30 2013 - 2 reports

Grifols, S.A. – American Depositary Upgraded by Zacks to Neutral (GRFS)

Grifols, S.A. – American Depositary (NASDAQ: GRFS) was upgraded by Zacks from an “underperform” rating to a “neutral” rating in a research report issued on Wednesday, Analyst Ratings Network reports. The firm currently has a $28.30 price objective on ... [Published Mideast Time - May 30 2013]

Entities: Grifols SA, Stocks, Berenberg Bank

First reported May 29 2013 - Updated May 29 2013 - 1 reports

Grifols Announces Transfer of Management of Melville, New York Plasma Fractionation Facility to Kedrion

) Today Grifols, S.A. (Grifols) announced that effective July 1, 2013, it will transfer management of the Melville, New York plasma fractionation facility to Kedrion. This action is being taken in accordance with previously disclosed terms of the 2011 ... [Published Noodls - May 29 2013]

Entities: Grifols SA, fractionation, Transfers, Talecris Biotherapeutics Holdings Corp, Plasma Proteins

First reported May 24 2013 - Updated May 24 2013 - 1 reports

GRIFOLS SA: Grifols holds its Ordinary General Shareholders Meeting

The company resumes cash dividend payment from 2013 Grifols holds its Ordinary General Shareholders' Meeting? Shareholders endorse the actions of the management team and ratify all the items on the agenda? The Board of Directors agrees to distribute ... [Published 4 Traders - May 24 2013]

Entities: Grifols SA, Stocks, Dividend, Face value

First reported May 23 2013 - Updated May 23 2013 - 3 reports

Grifols, Aradigm sign licensing agreement to develop, commercialize Pulmaquin

Grifols, a global healthcare company, and Aradigm, an emerging specialty pharmaceutical company focused severe respiratory diseases, have signed an exclusive worldwide license for Aradigm's proprietary formulations of inhaled ciprofloxacin (Pulmaquin ... [Published Center Watch - May 23 2013]

Entities: Aradigm Corporation, Grifols SA, Pulmaquin

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency

Study results presented at annual meeting of American Thoracic Society (ATS)PHILADELPHIA, May 22, 2013 /CNW/ - Grifols, a global healthcare company based in Barcelona, Spain, presented results from a study demonstrating that a higher dose of PROLASTIN©-C ... [Published Canada NewsWire - May 22 2013]

Entities: Grifols SA, Emphysema, Patient, Protein

First reported May 21 2013 - Updated May 21 2013 - 6 reports

Grifols Signs Deal to License Aradigm Corporation (ARDM)'s Pulmaquin for Up to $90.7 Million

BARCELONA, Spain & HAYWARD, Calif.--(BUSINESS WIRE)-- Grifols, S.A. (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS) (âGrifolsâ) and Aradigm Corporation (OTC BB:ARDM.OB) (âAradigmâ) today announced the signing of an exclusive, worldwide license for Aradigmâs proprietary ... [Published BioSpace - May 21 2013]

Entities: Pulmaquin, Aradigm Corporation, Grifols SA

Quotes

...Commenting on the report, an analyst from TechNavio's Healthcare team said: "Over the years, the Global Plasma market has been witnessing significant consolidation and as a result the positions of the leading players have shifted dramatically over the past decade. This trend is expected to continue during the forecast period as vendors attempt to strengthen or hold their market position. Market consolidation has resulted in stronger competitors that are better able to compete as sole-source vendors to end-users. For instance, Australia-based CSL Behring has become one of the world's leading fractionators through a series of acquisitions including its 2000 buyout of ZLB Behring and 2004 purchase of Aventis Behring. Grifols acquisition of Talecris Biotherapeutics has further consolidated the industry." According to the report, one of the major drivers is the increase in the aging population, which will lead to an increase in the number of immune deficiency...

Global Plasma Market 2013 - Report [Published Individual.com - 6 hours ago]

MarketInfoResearch.com's report "Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer's Disease" provides in-depth analysis of the global immunoglobulin market...

Immunoglobulins Market in Top Seven Markets Estimated to Reach $5.8 Billion by 2019 [Published Online PR News - Jun 08 2013]

"These data demonstrate that a 120 mg/kg dose of PROLASTIN-C provides closer to physiologic A1PI concentrations than the currently recommended 60 mg/kg dose and confirm the predictable PK profile of augmentation therapy" concluded Dr Mark Brantly, Professor of Medicine, University of Florida College of Medicine

Grifols announces encouraging results from AAT deficiency study [Published Individual.com - Jun 07 2013]

...O professor Manuel Sarasa "O estudo mostrou que nossos testes para Aβ no sangue encontram um alto nível de associação entre os níveis do peptídeo e a doença quando se comparando com pessoas saudáveis e pessoas com transtornos cognitivos leves" , ((MCI) os primeiros estágios perceptíveis de perda de memória.)

Alzheimer deixa rastros no sangue [Published PR Newswire - Jun 04 2013]

More Content

sort by: Date \| Relevance
New Report Available: F. Hoffmann-La Roche Ltd.... [Published SBWire - 46 mins ago]
Global Plasma Market 2013 - Report [Published Individual.com - 6 hours ago]
Alzheimer's Leaves Clues in Blood [Published KLFY - Jun 15 2013]
Cancer Diagnostics Partnering Terms and Agreements [Published Individual.com - Jun 13 2013]
Infectives Partnering Terms and Agreements Repo... [Published PredictWallStreet - Jun 12 2013]
Pre-Market Most Active for Jun 12, 2013 : CTB, ... [Published Nasdaq - Jun 12 2013]
Siemens Healthcare Market Share Analysis Report [Published Individual.com - Jun 10 2013]
Immunoglobulins Market in Top Seven Markets Est... [Published Online PR News - Jun 08 2013]
Grifols announces encouraging results from AAT ... [Published Individual.com - Jun 07 2013]
The wave of privatisations: in detail [Published Guardian.co.uk - Jun 05 2013]
Siemens Healthcare Market Share Analysis - New ... [Published SBWire - Jun 04 2013]
Continue to the full story [Published Nasdaq - Jun 04 2013]
Alzheimer deixa rastros no sangue [Published PR Newswire - Jun 04 2013]
El Alzheimer deja pistas en la sangre [Published PR Newswire - Jun 04 2013]
La maladie d'Alzheimer laisse des indices dans ... [Published PR Newswire - Jun 04 2013]
Alzheimer's Leaves Clues in Blood [Published Newswit.com - Jun 04 2013]
Cadence Pharmaceuticals Announces Strategic Pla... [Published Longitude Capital - Jun 03 2013]
Alzheimer's Leaves Clues in Blood [Published Asia Net - Jun 03 2013]
European broker round-up: Morgan Stanley review... [Published BIBM Banca Mora - Jun 03 2013]
Is the Patient Centered Outcomes Research Insti... [Published Health Care Renewal - May 31 2013]
Capital Markets: Debt & Equity – Chambers USA 2013 [Published Proskauer - May 31 2013]
Healthcare Marketers Trend Report: The Big Shift [Published Medical Marketing And Media - May 31 2013]
Immunoglobulin market to be worth $5.8 billion ... [Published MyNewsDesk - May 30 2013]
Grifols opens new immunoglobulin purification p... [Published Individual.com - May 30 2013]
Grifols, S.A. – American Depositary Upgraded by... [Published Mideast Time - May 30 2013]
Critical Care Market to 2019 - Growth from Fact... [Published Global Information Inc - May 30 2013]
Zacks Upgrades Grifols, S.A. – American Deposit... [Published American Banking News - Stock Ratings - May 29 2013]
Grifols Announces Transfer of Management of Mel... [Published Noodls - May 29 2013]
News story: Take a look at Catalonia [Published Cabinet Office - May 27 2013]
GRIFOLS SA: Grifols holds its Ordinary General ... [Published 4 Traders - May 24 2013]

Blogs

sort by: Date \| Relevance
Is the Patient Centered Outcomes Research Insti... [Published Health Care Renewal - May 31 2013] One of the biggest reasons our health care system seems so dysfunctional is that clinicians and patients have great difficulty determining what might be the appropriate management of particular clinical problems. Due to endless and sometimes deceptive ...
Immunoglobulins Market 2019 Demand in Primary I... [Published Zunia.org RSS - May 21 2013] RnRMarketResearch.com adds Immunoglobulins Market to 2019 Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) potentially supplemented by approvals for Alzheimers disease new report on its database. ...
PROFILNINE SD (Factor Ix Complex) Kit [Grifols ... [Published DailyMed Drug Label Updates for the last seven ... - May 14 2013] Updated Date: May 13, 2013 EST ...
PROFILNINE SD (Factor Ix Complex) Kit [Grifols ... [Published DailyMed Drug Label Updates for the last seven ... - May 13 2013] Updated Date: May 13, 2013 EST ...
ALBUTEIN (Albumin (Human)) Injection, Solution ... [Published DailyMed Drug Label Updates for the last seven ... - Mar 13 2013] Updated Date: Mar 13, 2013 EST ...

Press Releases

sort by: Date \| Relevance
Alzheimer deixa rastros no sangue [Published PR Newswire - Jun 04 2013]
El Alzheimer deja pistas en la sangre [Published PR Newswire - Jun 04 2013]
La maladie d'Alzheimer laisse des indices dans ... [Published PR Newswire - Jun 04 2013]
Grifols, S.A. and Aradigm Corporation Announce ... [Published Business Wire Photo/Multimedia News - May 21 2013]
Grifols, S.A. and Aradigm Corporation Announce ... [Published Business Wire Manufacturing News - May 21 2013]